DeCure for Ehlers-Danlos syndrome, periodontal type 2
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Ehlers-Danlos syndrome, periodontal type 2 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEhlers-Danlos syndrome, periodontal type 2 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ehlers-danlos syndrome, periodontal type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
complement C1s (C1S) — C1S is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2-hydroxy-1,1-dihydroxymethyl-ethylaminodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1ELV · 1.7 Å · ligand 2-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-ETHANESULFONIC ACID (NES). Experimental structure, not a prediction.
What the evidence adds up to
In a systematic review of periodontal Ehlers-Danlos syndrome (pEDS), early severe periodontitis was found in 98.4% of patients and gingival recession in 87.1%, based on thirty articles on pEDS and thirteen on other EDS subtypes. The review concluded that early severe periodontitis is the hallmark of pEDS and found no evidence it is part of the clinical phenotype of other EDS subtypes. It also noted that stringent analyses of periodontal manifestations in most EDS subtypes are missing.
A 2022 familial case report described a novel heterozygous missense mutation in C1R (c.674G>C, p.R225P) in a patient with pretibial hyperpigmentation and extended periodontitis but neither skin extensibility nor joint hypermobility. The authors suggested this mutation expands the definition of pEDS. A 2011 case report of two children with EDS stated there is no specific treatment for these patients, who usually present early-onset periodontitis leading to premature loss of permanent dentition, and noted the need to monitor bleeding tendency before and after dental treatment.
No drug treatment is mentioned in any of these abstracts. The systematic review identified that early severe periodontitis is the predominant feature of pEDS, but no intervention data were reported. What remains missing are any controlled trials of treatments for the periodontal disease in pEDS, as well as consistent diagnostic criteria that account for the variable presentation of skin and joint features, and funding for prospective studies that could stratify patients by specific C1R or C1S mutations.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal Of Clinical Periodontology · 2017 · 46 citations
Periodontal manifestations of Ehlers–Danlos syndromes: A systematic review
AbstractAIM: Ehlers-Danlos syndromes (EDS) are a group of inherited connective tissue disorders, characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. Periodontal EDS (pEDS) is a specific EDS subtype caused by heterozygous mutations in complement 1 subunit genes C1R and C1S, with early severe periodontitis as predominant clinical feature. We aimed to systematically assess the spectrum of periodontal abnormalities in all EDS subtypes. MATERIALS AND METHODS: An electronic and manual search was conducted in three databases (Medline, LIVIVO, CENTRAL). Publications of all study designs written in English/German without date restriction evaluating periodontal features in EDS were included. RESULTS: Thirty articles on pEDS and thirteen articles on other EDS subtypes were analysed. In pEDS, early severe periodontitis (98.4%) and gingival recession (87.1%) are the predominant features. Reports on periodontal manifestations in other EDS subtypes are rare. Described were severe gingival enlargement in dermatosparaxis EDS, and localized periodontal breakdown related to teeth with shortened roots in classical EDS (n = 3, respectively). CONCLUSION: Early severe periodontitis is the hallmark of pEDS; there is no evidence that it is part of the clinical phenotype of other EDS subtypes. Stringent analyses of periodontal manifestations in most EDS subtypes are missing. Prospero registration number CRD42017056889.
A familial case of periodontal <scp>Ehlers–Danlos</scp> syndrome lacking skin extensibility and joint hypermobility with a missense mutation in <scp><i>C1R</i></scp>
AbstractPeriodontal Ehlers-Danlos syndrome (pEDS) is an autosomal-dominant disorder first described by Stewart in 1977 that is characterized by severe gingival recession and periodontitis that triggers premature loss of permanent teeth and alveolar bone absorption. It was recently shown that pEDS is caused by a heterozygous missense mutation in C1R or C1S, which encode complement 1 proteases. Here, we report a familial case of pEDS with a novel heterozygous missense mutation, c.674G>C (p.R225P), in C1R (NM_001733.4). The case exhibited pretibial hyperpigmentation and extended periodontitis but neither skin extensibility nor joint hypermobility, suggesting that this mutation will expand the definition of pEDS.
Dental Management of Children with Ehlers-Danlos syndrome-Report of Two
AbstractEhlers-Danlos syndrome (EDS) is a heterogeneous group of inheritable connective tissue disorders. There are collagen defects caused by gene mutation. No uniform guideline can be used to treat these patients due to multi-organ involvement and varied presentations of this disease, such as poor wound healing ability, hypermobile joint. However, there is no specific treatment for these patients.These patients usually present early-onset periodontitis leading to premature loss of permanent dentition. The bleeding tendency needs to be monitored before and after dental treatment. Dentists need to minimize bleeding during procedure. We report two cases with Ehlers-Danlos syndrome who presented extensive dental caries, and mental retardation. They received comprehensive dental treatment under general anesthesia to minimize the trauma from their uncooperative behavior.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
